CytRx Corp. is changing by taking up the torch of RNA interference technology through license agreements with the University of Massachusetts Medical School. (BioWorld Today)

CytRx Corp. is changing by taking up the torch of RNA interference technology through license agreements with the University of Massachusetts Medical School. (BioWorld Today)

With the completion of the Pfizer Inc.-Pharmacia Corp. merger, the question that rises to the surface is this: Now that a big fish swallowed a rival and got bigger, what happens to the rest of the school in the pharmaceutical pond? (BioWorld Today)

With the completion of the Pfizer Inc.-Pharmacia Corp. merger, the question that rises to the surface is this: Now that a big fish swallowed a rival and got bigger, what happens to the rest of the school in the pharmaceutical pond? (BioWorld Today)

Genzyme General's first-quarter revenue blossomed nicely and the company hit its earnings-per-share estimates, but the revelation of a data delay from a Renagel trial dropped the company's stock Wednesday. (BioWorld Today)

Genzyme General's first-quarter revenue blossomed nicely and the company hit its earnings-per-share estimates, but the revelation of a data delay from a Renagel trial dropped the company's stock Wednesday. (BioWorld Today)